New drug aims to shield kidneys during heart surgery
NCT ID NCT07661940
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether an experimental drug called SP16 can prevent acute kidney injury in people with chronic kidney disease who are having heart surgery with a heart-lung machine. About 120 participants will be randomly assigned to receive either SP16 or a placebo, and neither they nor their doctors will know which they got. The goal is to see if SP16 reduces kidney damage caused by inflammation and reduced blood flow during surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SP16
What this could lead to
If it works, this could point toward a way to prevent kidney damage during heart surgery in patients with existing kidney problems.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. SP16 has been tested in only 28 people before, and its effectiveness is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Universitätsklinikum Erlangen
Erlangen, Bavaria, 91054, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••